CCDC6 and hypoparathyroidism-retardation-dysmorphism syndrome: Considering that CCDC6 physical or functional impairment significantly reduces γH2AX foci formation, we conclude that “CCDC6 inactive” status seems to be a valuable tool to identify patients with HRD eligible for PARPi therapy who might otherwise be excluded based solely on RAD51 assay unsuitability.